Acquired Nicholas Laboratories, marking our entry into pharmaceuticals.
Commissioned our first formulation plant in Pithampur, Madhya Pradesh, expanding operations in 1992.
Renamed Nicholas Laboratories Ltd. to Nicholas Piramal India Ltd.
Entered into a joint venture with Allergan, a leader in ophthalmic products.
Acquired Roche India’s domestic formulations and nutrition products/ services business.
Acquired Boehringer Mannheim's formulation plant in Mahad.
Acquired the bulk drug division of Sumitra Pharmaceutical and Chemical Ltd., Hyderabad.
Boehringer Mannheim fully acquired.
Began collaborative research in gene technology with the Centre for Biochemical Technology.
Acquired ICI Pharma.
Acquired Global Bulk Drugs.
Acquired Avecia Pharmaceuticals.
Acquired Morpeth facility from Pfizer.
Greenfield investment in Ahmedabad (PPDS)
Acquired Oxygen Bio Research, a CRO based in Ahmedabad.
Piramal Healthcare renamed to Piramal Enterprises, integrating pharma, Financial Services (FS), and new businesses created / acquired – FS and DRG.
Acquired Kentucky-based CDMO Coldstream Laboratories Inc.
Acquired Ash Stevens Inc., a U.S.-based developer specializing in high-potency APIs.
Acquired solid oral dosage drug product facility in Sellersville, Pennsylvania, from G&W Laboratories Inc.
Becomes a subsidiary of Piramal Enterprises and receives strategic growth investment by Carlyle.
Acquired Hemmo Pharmaceuticals, a leading Indian manufacturer of peptide APIs.
Acquired a minority stake in Yapan Bio, an Indian CDMO specializing in biologics and vaccines.
NCLT approves Piramal Enterprises demerger and Piramal Pharma Limited lists on BSE and NSE
Opens a new state-of-the-art API manufacturing facility in Aurora, Canada.
Opens a new state-of-the-art API manufacturing facility in Riverview, Michigan,
Opens its expanded antibody-drug conjugate (ADC) manufacturing facility in Grangemouth, Scotland, UK.
